[1]陈书德,王宏光,张文智,等.腹腔镜下射频消融与经皮射频消融治疗原发性肝癌[J].南方医科大学学报,2018,(09):1147.[doi:10.12122/j.issn.1673-4254.2018.09.21]
点击复制

腹腔镜下射频消融与经皮射频消融治疗原发性肝癌()
分享到：

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2018年09期
页码:
1147
栏目:
出版日期:
2018-09-30

文章信息/Info

Title:
Clinical application of laparoscopy-assisted and percutaneous radiofrequency ablation for hepatocellular carcinoma
作者:
陈书德; 王宏光; 张文智; 陈继业; 卢鹏
关键词:
肝细胞癌; 腹腔镜检查; 射频消融
Keywords:
hepatocellular carcinoma;  laparoscopy;  radiofrequency ablation
DOI:
10.12122/j.issn.1673-4254.2018.09.21
摘要:
目的探讨腹腔镜下射频消融（LRFA）与经皮射频消融(PRFA)治疗原发性肝癌的疗效和安全性。方法回顾性分析2013 年9月~2016年9月解放军总院海南分院肝胆外科60例HCC患者78个肿瘤结节，根据治疗方法不同分为LRFA组30例46个肿 瘤结节，PRFA组30例32个肿瘤结节。LRFA组行LRFA治疗，PRFA组采用PRFA，术后随访3年，比较两组完全消融率、严重并 发症、复发率及总生存率。结果LRFA组术后瘤体完全消融率为95.65%（44/46），PRFA组为93.75%（30/32），两组的完全消融 率比较差异无统计学意义（P>0.05）。两组严重并发症发生率LRFA组为0%（0/30），PRFA组为6.7%（2/30），两组严重并发症发 生率比较差异有统计学意义（P<0.05）。LRFA组复发率13.33%（4/30），复发时间为6~32月；PRFA组复发率23.33%（7/30），复发 时间为4~34 月，两组复发率比较差异有统计学意义（P<0.05）。两组1、3 年总生存率：LRFA组为96.15%、55.12%，PRFA组为 93.73%、48.54%，两组1、3年总生存率比较差异无统计学意义（P>0.05）。结论LRFA与PRFA都是治疗原发性肝癌的有效手 段，但是LRFA的复发率和严重并发症的发生率较低，安全性更高，尤其在治疗特殊部位肝癌更具优势。
Abstract:
Objective To compared the efficacy of laparoscopy- assisted radiofrequency ablation (LRFA) and percutaneous radiofrequency ablation (PRFA) for the treatment of hepatocellular carcinoma (HCC). Methods Between September, 2013 and September, 2016, a total of 60 HCC patients with 78 tumor nodules underwent LRFA (30 cases with 46 tumor nodules) and PRFA (30 cases with 32 tumor nodules) in our hospital. The patients were followed up for 3 years to compare the complete ablation rate, serious complications, recurrence rate and long-term survival rate between the two groups. Results The patients receiving LRFA had a complete ablation rate of 95.65% (44/46), significantly higher than the rate of 93.75% (30/32) in PRFA group (P>0.05). Significant differences were found between LRFA and PRFA groups in the incidence of serious complications [0 vs 6.7% (2/30), P<0.05] and recurrence rate [13.33% (4/30) vs 23.33% (7/30), P<0.05]. The 1-and 3-year overall survival rates of the patients were 96.15% and 55.12% in LRFA group and 93.73% and 48.54% in PRFA group, respectively (P>0.05). Conclusions Both LRFA and PRFA are effective for HCC treatment, but is associated with a lower recurrence rate, fewer serious complications, a better treatment safety and a better applicability for tumor in difficult locations.

相似文献/References:

[1]郭丹,陈娜娜,侯连兵,等.前列腺素E2活化EP2受体促进肝癌细胞增殖[J].南方医科大学学报,2011,(09):1564.
[2]李湘竑,钟克波,刘延,等.索拉菲尼治疗肝癌肝移植术后肿瘤复发患者的疗效及安全性分析[J].南方医科大学学报,2011,(09):1608.
[3]陈可和,梁博,邹镇洪,等.Rheb和Rheb’D60K突变基因重组慢病毒载体的构建、鉴定及其对肝癌细胞凋亡的影响[J].南方医科大学学报,2012,(03):341.
[4]赵爱国,吴曙光.沉默CDK7基因对HepG2细胞株的抗增殖作用[J].南方医科大学学报,2005,(01):58.
　ZHAO Ai-guo,WU Shu-guang.Effect of CDK7 gene silencing against hepatoblastoma HepG2 cell proliferation[J].Journal of Southern Medical University,2005,(09):58.
[5]余元龙,季明芳,何洁冰,等.紫杉醇、5-氟脲嘧啶抑制肝癌细胞BEL-7402生长和诱导凋亡的比较[J].南方医科大学学报,2005,(07):864.
　YU Yuan-long,JI Ming-fang,HE Jie-bing,et al.Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells:a comparative study[J].Journal of Southern Medical University,2005,(09):864.
[6]金吴东,陈龙华,穆峰.外源性mTκα基因抑制肝癌细胞HepG2的生长[J].南方医科大学学报,2004,(10):1133.
　JIN Wu-dong,CHEN Long-hua,MU Feng.Exogenous mTκα gene inhibits the growth of HepG2 heptocellular carcinoma cells[J].Journal of Southern Medical University,2004,(09):1133.
[7]苟学萍,徐惠成.腹腔镜检查对围绝经和绝经后妇女盆腔肿块的诊断价值[J].南方医科大学学报,2004,(05):589.
　GOU Xue-ping,XU Hui-cheng.Diagnostic value of laparoscopy for pelvic masses in perimenopausal and postmenopausal women[J].Journal of Southern Medical University,2004,(09):589.
[8]陈志丰,梁宏,张祥松,等.肝癌治疗后甲胎蛋白增高患者的18F-FDG PET/CT与增强CT对照研究[J].南方医科大学学报,2012,(11):1615.
[9]李超,涂康生,郑鑫,等.MicroRNA-218在肝细胞癌中的表达及功能[J].南方医科大学学报,2013,(08):1127.
[10]黄俊海,周杰.符合Milan标准肝细胞癌患者行肝移植和肝切除术预后分析[J].南方医科大学学报,2014,(03):406.

更新日期/Last Update: 1900-01-01